{
    "title": "Research to Accelerate Cures and Equity for Children Act",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Research to Accelerate Cures and \nEquity for Children Act'' or the ``RACE for Children Act''.\n\nSEC. 2. DRUG DEVELOPMENT FOR PEDIATRIC CANCER.\n\n    (a) Molecular Targets Regarding Cancer Drugs.--Section 505B of the \nFederal Food, Drug, and Cosmetic Act (21 U.S.C. 355c) is amended--\n            (1) in subsection (a)(2)(A)(i) by striking ``product for \n        the claimed indications in all relevant pediatric \n        subpopulations; and'' and inserting ``product in all relevant \n        pediatric subpopulations--\n                                    ``(I) for the claimed indications; \n                                or'';\n                                    ``(II) for a pediatric cancer \n                                indication, if the drug is intended for \n                                the treatment of an adult cancer and is \n                                directed at a molecular target \n                                considered to be germane to the growth \n                                and progression of such pediatric \n                                cancer; and'';\n            (2) in subsection (b)(1)--\n                    (A) by amending subparagraph (A)(i) to read as \n                follows:\n                    ``(A)(i) the drug or biological product is used for \n                a substantial number of pediatric patients--\n                            ``(I) for the labeled indications; or\n                            ``(II) for a pediatric cancer indication, \n                        if the drug is intended for the treatment of an \n                        adult cancer and is directed at a molecular \n                        target considered to be germane to the growth \n                        and progression of such pediatric cancer; \n                        and''; and\n                    (B) by amending subparagraph (B) to read as \n                follows:\n                    ``(B) there is reason to believe that the drug or \n                biological product would represent a meaningful \n                therapeutic benefit over existing therapies for \n                pediatric patients--\n                            ``(i) for one or more of the claimed \n                        indications; or\n                            ``(ii) for a pediatric cancer indication, \n                        if the drug is intended for the treatment of an \n                        adult cancer and is directed at a molecular \n                        target considered to be germane to the growth \n                        and progression of such pediatric cancer; or''; \n                        and\n            (3) by amending paragraph (2) of subsection (c) to read as \n        follows:\n            ``(2) the drug or biological product is in a class of \n        products, is for an indication, or is directed at a specific \n        molecular target in an adult cancer and such molecular target \n        is germane to the growth or progression of cancer in a \n        pediatric cancer, for which there is need for additional \n        options.''.\n    (b) Early Meeting on Pediatric Study Plan.--\n            (1) In general.--Clause (i) of section 505B(e)(2)(C) of the \n        Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355c(e)(2)(C)) \n        is amended to read as follows:\n                            ``(i) shall meet with the applicant--\n                                    ``(I) if requested by the applicant \n                                with respect to a drug that is intended \n                                to treat a serious or life-threatening \n                                disease or condition, to discuss \n                                preparation of the initial pediatric \n                                study plan, not later than the end-of-\n                                Phase 1 meeting (as such term is used \n                                in section 312.47(b) of title 21, Code \n                                of Federal Regulations, or successor \n                                regulations) or within 30 days of \n                                receipt of such request, whichever is \n                                later;\n                                    ``(II) to discuss the initial \n                                pediatric study plan as soon as \n                                practicable, but not later than 90 \n                                calendar days after the receipt of such \n                                plan under subparagraph (A); and\n                                    ``(III) to discuss any scientific \n                                or operational challenges that may be \n                                the basis of a deferral under \n                                subsection (a)(3) or a full or partial \n                                waiver under subsection (a)(4);''.\n            (2) Conforming changes.--Section 505B(e) of the Federal \n        Food, Drug, and Cosmetic Act (21 U.S.C. 355c(e)) is amended--\n                    (A) in the heading of paragraph (2), by striking \n                ``meeting'' and inserting ``meetings'';\n                    (B) in the heading of paragraph (2)(C), by striking \n                ``Meeting'' and inserting ``Meetings'';\n                    (C) in clauses (ii) and (iii) of paragraph (2)(C), \n                by striking ``no meeting'' each place it appears and \n                inserting ``no meeting under clause (i)(II)''; and\n                    (D) in paragraph (3) by striking ``meeting under \n                paragraph (2)(C)(i)'' and inserting ``meeting under \n                paragraph (2)(C)(i)(II)''.\n    (c) Orphan Drugs.--Section 505B(k) of the Federal Food, Drug, and \nCosmetic Act (21 U.S.C. 355c(k)) is amended by inserting ``except in \nthe case of a drug or biological product that is intended for the \ntreatment of an adult cancer and is directed at a molecular target \nconsidered to be germane to the growth and progression of a pediatric \ncancer,'' after ``regulation,''.\n    (d) Guidance.--Not later than 1 year after the date of enactment of \nthis Act, the Secretary of Health and Human Services, acting through \nthe Commissioner of Food and Drugs, shall issue guidance on the \nimplementation of the amendments to section 505B of the Federal Food, \nDrug, and Cosmetic Act (21 U.S.C. 355c) made by this section, \nincluding--\n            (1) study designs;\n            (2) molecular targets considered to be germane to the \n        growth and progression present in one or more cancers in \n        pediatric populations that may be appropriate for assessment \n        under such section 505B, as so amended; and\n            (3) considerations for implementation of such section 505B, \n        as so amended, and waivers of the requirements of such section \n        505B with regard to molecular targets for which several drugs \n        may be under investigation.\n    (e) Applicability.--This section and the amendments made by this \nsection apply with respect to applications for a drug submitted under \nsection 505 of the Federal Food, Drug, or Cosmetic Act (21 U.S.C. 355) \nor section 351 of the Public Health Service Act (42 U.S.C. 262) on or \nafter the date that is 18 months after the date of enactment of this \nAct.\n    (f) Report to Congress.--Section 508(b) of the FDA Safety and \nInnovation Act (21 U.S.C. 355c-1(b)) is amended--\n            (1) in paragraph (10), by striking ``; and'' and inserting \n        ``;''; and\n            (2) by striking paragraph (11) and inserting the following:\n            ``(11) an assessment of the impact of the amendments to \n        such section 505B made by the RACE for Children Act on \n        pediatric labeling of drugs and pediatric labeling of \n        molecularly targeted drugs for the treatment of cancer;\n            ``(12) an assessment of the efforts of the Secretary to \n        implement the plan developed under section 505C-1 of the \n        Federal Food, Drug, and Cosmetic Act, regarding earlier \n        submission of pediatric studies under sections 505A and 505B, \n        including--\n                    ``(A) the average length of time after the approval \n                of an application under section 505(b)(1) of the \n                Federal Food, Drug, and Cosmetic Act (21 U.S.C. \n                355(b)(1)) before studies conducted pursuant to such \n                sections 505A or 505B are completed, submitted, and \n                incorporated into labeling;\n                    ``(B) the average length of time after the receipt \n                of a proposed pediatric study request before the \n                Secretary responds to such request;\n                    ``(C) the average length of time after the \n                submission of a proposed pediatric study request before \n                the Secretary issues a written request for such \n                studies;\n                    ``(D) the number of written requests issued for \n                each investigational new drug prior to the submission \n                of an application under section 505(b)(1) of the \n                Federal Food, Drug, and Cosmetic Act; and\n                    ``(E) the average number, and range of numbers, of \n                amendments to written requests issued;\n            ``(13) a list of sponsors of applications or holders of \n        approved applications who received exclusivity under such \n        section 505A after receiving a letter issued under such section \n        505B(d)(1) and before the studies referred to in such letter \n        were completed and submitted; and\n            ``(14) a list of assessments required under subsection \n        (a)(2)(A)(i)(II), and (b)(1)(B)(ii) of section 505B.''.\n    (g) Rule of Construction.--Nothing in this section, including the \namendments made by this section, shall limit the authority of the \nSecretary of Health and Human Services to issue written requests under \nsection 505A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. \n355a).\n\nSEC. 3. IMPROVING THE TIMELINESS OF PEDIATRIC STUDIES.\n\n    (a) Informing Internal Review Committee.--Section 505A(f) of the \nFederal Food, Drug, and Cosmetic Act (21 U.S.C. 355a(f)) is amended by \nadding at the end the following:\n            ``(7) Informing internal review committee.--The Secretary \n        shall provide to the committee referred to in paragraph (1) any \n        response issued to an applicant or holder with respect to a \n        proposed pediatric study request.''.\n    (b) Action on Submissions.--Section 505A(d) of the Federal Food, \nDrug, and Cosmetic Act (21 U.S.C. 355a(d)) is amended--\n            (1) by redesignating paragraphs (3) through (5) as \n        paragraphs (4) through (6), respectively; and\n            (2) by inserting after paragraph (2) the following:\n            ``(3) Action on submissions.--The Secretary shall review \n        and act upon a submission of a proposed pediatric study request \n        or a sponsor's proposed amendment to a written request for \n        pediatric studies within 120 days of the submission.''.\n    (c) Study.--The Secretary of Health and Human Services, acting \nthrough the internal review committee established under section 505C of \nthe Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355d) shall, not \nlater than one year after the date of enactment of this Act, develop \nand implement a plan to achieve, when appropriate, earlier submission \nof pediatric studies under section 505A of the Federal Food, Drug, and \nCosmetic Act (21 U.S.C. 355a). Such plan shall include recommendations \nto achieve--\n            (1) earlier discussion of proposed pediatric study requests \n        and written requests with sponsors, and if appropriate, at the \n        meeting required under section 505B(e)(2)(C) of the Federal \n        Food, Drug, and Cosmetic Act (21 U.S.C. 355c(e)(2)(C)), as \n        amended by section 2;\n            (2) earlier issuance of written requests for a pediatric \n        study under such section 505A, including for investigational \n        new drugs prior to the submission of an application under \n        section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act \n        (21 U.S.C. 355(b)(1)); and\n            (3) shorter timelines, when appropriate, for the completion \n        of studies pursuant to a written request under such section \n        505A.\n\nSEC. 4. NEONATOLOGY EXPERTISE.\n\n    Section 6(d) of the Best Pharmaceuticals for Children Act (21 \nU.S.C. 393a(d)) is amended by striking ``For the 5-year period \nbeginning on the date of enactment of this subsection, at'' and \ninserting ``At''."
}